Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Cash & Equivalents (2021 - 2025)

Historic Cash & Equivalents for Roivant Sciences (ROIV) over the last 5 years, with Q4 2025 value amounting to $1.5 billion.

  • Roivant Sciences' Cash & Equivalents fell 2574.06% to $1.5 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.5 billion, marking a year-over-year decrease of 2574.06%. This contributed to the annual value of $2.7 billion for FY2025, which is 5819.2% down from last year.
  • Latest data reveals that Roivant Sciences reported Cash & Equivalents of $1.5 billion as of Q4 2025, which was down 2574.06% from $1.2 billion recorded in Q3 2025.
  • In the past 5 years, Roivant Sciences' Cash & Equivalents ranged from a high of $6.7 billion in Q4 2023 and a low of $1.2 billion during Q3 2025
  • For the 5-year period, Roivant Sciences' Cash & Equivalents averaged around $2.5 billion, with its median value being $2.0 billion (2024).
  • In the last 5 years, Roivant Sciences' Cash & Equivalents skyrocketed by 33864.33% in 2023 and then plummeted by 7827.26% in 2025.
  • Quarter analysis of 5 years shows Roivant Sciences' Cash & Equivalents stood at $2.2 billion in 2021, then crashed by 31.02% to $1.5 billion in 2022, then surged by 338.64% to $6.7 billion in 2023, then tumbled by 70.29% to $2.0 billion in 2024, then decreased by 25.74% to $1.5 billion in 2025.
  • Its last three reported values are $1.5 billion in Q4 2025, $1.2 billion for Q3 2025, and $1.2 billion during Q2 2025.